Bright Minds Biosciences (NASDAQ:DRUG) Shares Gap Up – Here’s Why

Posted by Brian Himes on Oct 30th, 2026

Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Free Report)’s share price gapped up before the market opened on Wednesday. The stock had previously closed at $51.09, but opened at $54.25. Bright Minds Biosciences shares last traded at $54.0420, with a volume of 404 shares traded.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Zacks Research lowered shares of Bright Minds Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 15th. BTIG Research reiterated a “buy” rating and issued a $147.00 price objective on shares of Bright Minds Biosciences in a research note on Monday, August 17th. Lifesci Capital raised Bright Minds Biosciences to a “strong-buy” rating in a research report on Monday, September 28th. HC Wainwright restated a “buy” rating and issued a $145.00 price target on shares of Bright Minds Biosciences in a research report on Wednesday, August 19th. Finally, Oppenheimer cut shares of Bright Minds Biosciences to a “market perform” rating in a research note on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $144.71.

View Our Latest Research Report on Bright Minds Biosciences

Bright Minds Biosciences Trading Up 2.5%

The stock has a market capitalization of $551.59 million, a price-to-earnings ratio of -27.25 and a beta of -5.22. The stock has a fifty day moving average of $59.65 and a two-hundred day moving average of $73.48.

Bright Minds Biosciences (NASDAQ:DRUG – Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($1.22) by $1.05. Equities analysts expect that Bright Minds Biosciences Inc. will post -2.93 earnings per share for the current year.

Institutional Trading of Bright Minds Biosciences

Several institutional investors have recently modified their holdings of DRUG. Strs Ohio boosted its position in Bright Minds Biosciences by 200.0% during the first quarter. Strs Ohio now owns 2,700 shares of the company’s stock valued at $197,000 after acquiring an additional 1,800 shares during the last quarter. Engineers Gate Manager LP purchased a new position in shares of Bright Minds Biosciences during the second quarter valued at approximately $380,000. Seven Fleet Capital Management LP bought a new position in shares of Bright Minds Biosciences during the first quarter valued at about $467,000. Sei Investments Co. purchased a new stake in shares of Bright Minds Biosciences during the 1st quarter worth approximately $816,000. Finally, AdvisorShares Investments LLC lifted its stake in Bright Minds Biosciences by 26.8% in the first quarter. AdvisorShares Investments LLC now owns 12,613 shares of the company’s stock valued at $920,000 after purchasing an additional 2,669 shares during the last quarter. Institutional investors own 40.52% of the company’s stock.

About Bright Minds Biosciences

(Get Free Report)

Bright Minds Biosciences Inc is a biotechnology company focused on developing novel treatments for neurological and psychiatric disorders. The company’s research is centered on serotonergic compounds designed to provide therapeutic benefits associated with psychedelic medicines while potentially reducing unwanted effects such as hallucinations and cardiovascular or behavioral complications.

Bright Minds’ pipeline includes BMB-101, a selective serotonin 5-HT2C receptor agonist being developed for conditions including substance use disorders.